1Rinderknecht H, Haberfelde G, Maset R, et al. Pancreatic secretory abnormalities precede appearance of tumors of the pancreas in hamsters treated with bis-(2-oxopropyl)-N-nitrosamine. Dig Dis Sci, 1983, 28:526-538.
2Takahashi M, Furukawa F, Toyoda K, et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis, 1990,11:393-395.
3Wenger FA, Kilian M, Mautsch I, et al. Influence of octreotide on liver metastasis and heptic lipid peroxdation in BOP-induced pancreatic cancer in Syrian hamsters. Pancreas,2001,23:266-272.
4Wenger FA, Kilian M, Bisevac M, et al. Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer. Clin Exp Metastasis, 2002, 19:169-173.
5Schuller HM, Zhang L, Weddle DL, et al. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol, 2002, 128:525-532.
6Guo YS, Townsend CM Jr. Role of gastrointestinal hormones in pancreatic cancer. J Hepatobiliary Pancreat Surg, 2000, 7:276-285.
7Taylor PR, Dowling RH, Palmer TJ, et al. Induction of pancreatic tumours by longterm duodenogastric reflux. Gut, 1989 ,30:1596-1600.
8Oettle H, Arnold D, Riess H. Adjuvant therapy of pancreatic carcinoma. Schweiz Rundsch Med Prax,2000,89:2017-2025.
9Nanda GS, Sun FX, Hofmann GA, et al. Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in animal model. Anticancer Res, 1998, 18:1361-1366.
10Mohammad RM, Dugan MC, Mohamed AN, et al. Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas,1998, 16:19-25.
